Durgical
EN
Open the app

Haematopoietic stem cell transplant: the immunology

  • Process

A stem cell transplant replaces the whole blood and immune system; the new immune system can fight leukaemia but can also attack the patient.

Updated

What it is

Haematopoietic stem cell transplantation (HSCT) replaces a patient’s marrow with stem cells from the patient (autologous) or a donor (allogeneic). After conditioning, donor cells engraft and rebuild every blood and immune cell. In allogeneic transplant, donor T and NK cells can kill remaining leukaemia (graft-versus-leukaemia) but can also cause graft-versus-host disease, and immunity recovers slowly, shaping a predictable infection timeline.

Step by step

  1. Stem cells come from marrow, from blood after mobilisation with G-CSF, or from cord blood.
  2. Conditioning (chemotherapy ± radiation) destroys diseased marrow and suppresses host immunity so the graft is not rejected.
  3. Stem cells are infused into a vein and home to the bone marrow.
  4. Neutrophils recover first, within weeks; platelets later; chimerism studies confirm donor origin.
  5. NK cells return early; T cells take months to years, because thymic output is limited, especially in adults.
  6. Donor T and NK cells kill leukaemia (GVL) and may attack host tissues (GVHD).
  7. Patients are revaccinated from scratch; live vaccines wait for immune recovery without GVHD.

Autologous vs allogeneic transplant

FeatureAutologousAllogeneic
SourceThe patient’s own stem cellsA donor: matched sibling, unrelated, haploidentical or cord blood
Main usesMyeloma, relapsed lymphoma (allows intensive chemotherapy)Acute leukaemias, myelodysplasia, aplastic anaemia, SCID, thalassaemia, sickle cell disease
GVHDNoYes
Graft-versus-leukaemiaNoYes
Graft rejectionNot an issuePossible (host T and NK cells)

Clinical notes

  • Infection timeline: early bacteria and fungi (neutropenia, mucositis); then CMV reactivation and other viruses; late encapsulated bacteria, especially with chronic GVHD.
  • EBV-driven post-transplant lymphoproliferative disorder can occur when T cells are depleted.
  • Donor lymphocyte infusion can treat relapse by boosting graft-versus-leukaemia, at the risk of GVHD.
  • Reduced-intensity conditioning relies on graft-versus-leukaemia rather than on chemotherapy to cure.

Common traps

  • Autologous transplant cures leukaemia through graft-versus-leukaemia: it has no GVL, it only rescues the marrow after intensive chemotherapy.
  • Removing all donor T cells is ideal: it lowers GVHD but raises relapse, graft failure and EBV lymphoproliferation.
  • Engraftment means the immune system is back: neutrophils return in weeks, but T-cell immunity takes months to years.
  • Childhood vaccines still protect after allogeneic transplant: immune memory is lost, so the patient is revaccinated from scratch.

Test yourself

Think of the answer, then tap the question to see it.

Why is graft-versus-leukaemia inseparable in practice from graft-versus-host disease?

Both are attacks by donor T and NK cells on recipient cells; the same alloreactivity that kills leukaemia also damages host tissues.

Why does GVHD not occur after autologous transplant?

The stem cells and lymphocytes are the patient's own, so they recognise the host as self.

Three months after allogeneic transplant, neutrophils are normal but CMV reactivates. Why is the patient still vulnerable?

T-cell recovery lags far behind neutrophils, and CMV control depends on T cells; GVHD prophylaxis adds to the gap.

A patient relapses after allogeneic transplant. What immune treatment can boost GVL, and what is its risk?

Donor lymphocyte infusion; it boosts graft-versus-leukaemia but can trigger GVHD.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of immunology

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: Stem Cell Transplants in Cancer Treatment (National Cancer Institute (NIH), 2023); Bone marrow transplant (MedlinePlus, US National Library of Medicine, 2024); Graft-versus-host disease (MedlinePlus, US National Library of Medicine, 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.